Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting

AONC 12.30.2024

Full Press ReleaseSEC FilingsOur AONC Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - MidAmerica Cancer Care Joins American Oncology Network
  • 01.21.2025 - Florida Oncology and Hematology Relocates Fort Myers Clinic
  • 01.15.2025 - American Oncology Network Appoints Charlie Goddard as General Counsel

Recent Filings

  • 01.02.2025 - 15-15D Suspension of duty to report [Section 13 and 15(d)]
  • 12.26.2024 - 8-K/A Current report
  • 12.19.2024 - EX-99.1 EX-99.1

Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting

December 30, 2024/inNews/byAON Website Manager

INDIANAPOLIS, IN., Dec. 30, 2024— Board-certified medical oncologists,M. Sarfraz Nawaz, MDandRuemu E. Birhiray, MDfrom community oncology practiceHematology Oncology of Indiana(HOI), a partner practice ofAmerican Oncology Network(AON) (OTCQX: AONC), presented clinically meaningful and socially impactful research findings at the 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 7-10 in San Diego.

The ASH Annual Meeting is recognized as a premier event for hematology research, with more than 5,000 scientific abstracts submitted each year. Accepted abstracts undergo rigorous peer review, with selected presentations showcasing significant and innovative contributions to the field.

The following HOI physician-researchers presented at the conference:

  • M. Sarfraz Nawaz
    • Presented and served as co-author of two studies:
      • Collaborative Strategies to Enhance Treatment and Integration of Cellular Therapies in Multiple Myeloma: Results from Nationwide Multiple Myeloma Patient and Provider Surveys
      • Advancing Patient-Centered Care to Overcome Health Disparities in Multiple Myeloma: Key Findings from a Quality Improvement Initiative
    • Co-authoredAdvancing the Integration of CAR T-Cell Therapy in Community Oncology Centers: Key Findings from a Transformative Quality Improvement Initiative, published online in the November supplemental issue of Blood.
    • Moderated the ASH Satellite Symposium,Accelerating the Adoption of the Latest Evidence on Sequencing Therapies for Multiple Myeloma Across Practice Settings, held Dec. 6.
  • Ruemu E. Birhiray
    • Co-authored three studies:
      • In-class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received.
      • Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study.
      • A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action.

“Being selected to present research at the ASH Annual Meeting is a significant honor,” saidDr. M. Sarfraz Nawaz. “With thousands of submissions considered, these selected abstracts highlight vital advancements in cancer care. I congratulate my colleagues on their achievements and dedication to improving patient outcomes.”

“The evolving field of cancer research continually brings transformative findings that revolutionize patient care,” saidStephen “Fred” Divers, MD, AON chief medical officer. “Our physicians’ commitment to ongoing education and innovation reflects their dedication to advancing cancer care through impactful research that improves patient outcomes and expands access to quality care.”

###

American Oncology NetworkAmerican Oncology Network(AON) (OTCQX: AONC) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 250 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visitAONcology.comor follow us onLinkedIn,Facebook,X (formerly Twitter)andYouTube.

About Hematology Oncology of Indiana

Hematology Oncology of Indianais a community-based medical oncology and hematology practice providing treatment for patients diagnosed with all types of cancer and blood disorders. Through compassionate care that centers around the patient, Hematology Oncology of Indiana strives to provide the best possible experience to patients and their families throughout the healthcare journey. Learn more athematologyoncology.com.

Media Contact:Karen Riley SawyerAmerican Oncology NetworkKaren.Sawyer@AONcology.com

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Reddit
  • Share by Mail
https://www.aoncology.com/wp-content/themes/aon-enfold-child/images/AON_Logo_White.svg00AON Website Managerhttps://www.aoncology.com/wp-content/themes/aon-enfold-child/images/AON_Logo_White.svgAON Website Manager2024-12-30 08:00:002024-12-31 02:52:06Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com